Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Title:
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Author:
Geyer, C.E. Sikov, W.M. Huober, J. Rugo, H.S. Wolmark, N. O’Shaughnessy, J. Maag, D. Untch, M. Golshan, M. Lorenzo, J. Ponce Metzger, O. Dunbar, M. Symmans, W.F. Rastogi, P. Sohn, J.H. Young, R. Wright, G.S. Harkness, C. McIntyre, K. Yardley, D. Loibl, S.